BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30876683)

  • 1. New and Novel Therapies for Gynecologic Cancers.
    Richardson DL
    Semin Oncol Nurs; 2019 Apr; 35(2):217-219. PubMed ID: 30876683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
    Pan K; Gong J; Huynh K; Cristea M
    Target Oncol; 2019 Jun; 14(3):269-283. PubMed ID: 31069647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic gynecologic malignancies: advances in treatment and management.
    Chan JK; Chow S; Bhowmik S; Mann A; Kapp DS; Coleman RL
    Clin Exp Metastasis; 2018 Aug; 35(5-6):521-533. PubMed ID: 29931499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing Drug Development in Gynecologic Malignancies.
    Beaver JA; Coleman RL; Arend RC; Armstrong DK; Bala S; Mills GB; Sood AK; Herzog TJ
    Clin Cancer Res; 2019 Aug; 25(16):4874-4880. PubMed ID: 31126961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenesis therapy in gynecologic malignancies.
    Liu FW; Cripe J; Tewari KS
    Oncology (Williston Park); 2015 May; 29(5):350-60. PubMed ID: 25979545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials in gynecologic oncology: Past, present, and future.
    Annunziata CM; Kohn EC
    Gynecol Oncol; 2018 Feb; 148(2):393-402. PubMed ID: 29212614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers.
    Schmid BC; Oehler MK
    Curr Treat Options Oncol; 2015 Jan; 16(1):318. PubMed ID: 25750175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates in the Use of Targeted Therapies for Gynecologic Cancers.
    Cantillo E; Blanc-Durand F; Leary A; Slomovitz BM; Fuh K; Washington C
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438582. PubMed ID: 38788185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating antibody drug conjugates in the management of gynecologic cancers.
    Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
    Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
    Muggia FM
    Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic-Based Therapy of Gynecologic Malignancies.
    Markman M
    Acta Med Acad; 2019 Apr; 48(1):84-89. PubMed ID: 31264436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Therapies in Gynecologic Cancer.
    Bejar FG; Oaknin A; Williamson C; Mayadev J; Peters PN; Secord AA; Wield AM; Coffman LG
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-17. PubMed ID: 35594502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immuno-oncology for Gynecologic Malignancies.
    How J; Patel A; Jazaeri A
    Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.
    Wolford JE; Ferrigni E; Margul D; Herzog TJ
    Curr Oncol Rep; 2022 Jul; 24(7):889-904. PubMed ID: 35347591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA grants accelerated approval for targeted therapy for platinum-resistant gynecologic cancers.
    Nierengarten MB
    Cancer; 2023 Mar; 129(5):656. PubMed ID: 36744309
    [No Abstract]   [Full Text] [Related]  

  • 18. U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
    Arora S; Narayan P; Ison G; Berman T; Suzman DL; Wedam S; Prowell TM; Ghosh S; Philip R; Osgood CL; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2022 Mar; 28(6):1058-1071. PubMed ID: 34711631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
    Gadducci A; Guerrieri ME
    Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapies for advanced, recurrent, and metastatic endometrial cancers.
    Makker V; Green AK; Wenham RM; Mutch D; Davidson B; Miller DS
    Gynecol Oncol Res Pract; 2017; 4():19. PubMed ID: 29214032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.